February 12, 2014
Leuven, Belgium - Terumo Europe N.V. announced today that it received the prestigious prize in the category Quality of Life for NANOPASS® 34 - The World's Thinnest Pen Needle 1 - at the Pharmapack Europe Conference & Exhibition in Paris. At this event, the world's pharmaceutical development experts gathered to discuss and review new developments and innovations in drug delivery and pharmaceutical packaging.
Patients have long been in search of virtually painless injections. Terumo has made this possible with the advanced NANOPASS® 34 - The World's Thinnest Pen Needle. Year after year we develop our products using our long-term experience of metal and alloy processing combined with Japanese precision craftsmanship. This expertise, which we sometimes compare to forging the Japanese Katana swords, enabled us to create the World's Thinnest Pen Needle using our tapered needle technology. Our tapered needles are folded with precision, not extruded.
NANOPASS® 34 advantages can be summarized as follows:
For various applications ...
Recent developments indicate biopharmaceutical drugs are becoming more viscous, creating challenges to the injectability. Terumo's tapered needle technology makes it possible to minimize needle size enhancing patient comfort, while still allowing the drug to flow smoothly through the needle. So we noticed that needles - made with tapered needle technology - are virtually pain free, whilst still can be used to inject more viscous solutions.
"For many years Terumo's challenging goal is and remains: Less pain every day ... and with NANOPASS® 34 we can just do that. Innovation is part of Terumo's heritage and this award-winning pen-needle with its patented tapered needle technology adds well to our parenteral drug delivery portfolio and value proposition to the pharmaceutical industry, along with PLAJEX™ polymer prefilled syringes, combined with i-coating™, our silicone-oil free prefilled syringe system", said Juichi (Jim) Takeuchi, Executive Officer and President of Global Pharmaceutical Solutions, Terumo Corporation.
PLAJEX™ ready-to-fill polymer syringes are born out of Terumo's profound knowledge of life sciences, pharmaceutical operations and prefilled syringe manufacturing. PLAJEX™ provides a silicone oil-free syringe system, using a novel and proprietary i-coating™ technology on plunger stoppers for reliable functionality and achieving very low sub-visible particles. PLAJEX™ is steam sterilized, avoiding the generation of radicals, impacting biotherapeutics.
A dedicated Global Pharmaceutical Solutions group works hand-in-hand with the pharmaceutical industry to translate ideas into commercialised products and services. This team integrates Terumo's industry expertise with its technology platforms, creating results which are customised to your needs and often surpass the original expectations. Global Pharmaceutical Solutions offers almost 100 years of experience with advanced skills that cover product design, development, quality management, manufacturing, operations, logistics, customer service, regulatory expertise and numerous other business processes.
Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with $4billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures, and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures, and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use.
Terumo contributes to society by providing valued products and services to the healthcare market and by responding to the needs of healthcare providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange and is a component of the Nikkei, Japan's leading stock index.
Based on research by Terumo Corporation in August 2012
Corporate Communication Dept., Terumo Corporation
(Notice) Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.